Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1808239 | 0.83 | HTT (0.38) | GAAHTTSMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL1798634 | 0.83 | GAA (0.38) | GAAHTTSMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL2943345 | 0.81 | MEN1 (0.40) | GAAALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL2943359 | 0.80 | HPGD (0.41) | HTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL4036735 | 0.80 | MAPT (0.43) | GAAHTTSMN1; SMN2ALDH1A1CYP2D6 | |
| SCHEMBL1800410 | 0.80 | OPRM1 (0.32) | HTTALDH1A1 | |
| SCHEMBL2942901 | 0.79 | CHRNA4 (0.39) | GAAHTTALDH1A1 | |
| SCHEMBL2939777 | 0.79 | MAPT (0.43) | GAAL3MBTL1CYP2C19 | |
| SCHEMBL2934155 | 0.79 | CHRM2 (0.47) | HTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL2942484 | 0.79 | SMN1; SMN2 (0.41) | HTTSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1730147-B1 | SUBSTITUTED 1,4,8-TRIAZASPIRO[4,5]DECAN-2-ON COMPOUNDS FOR USE IN THE TREATMENT OF OBESITY | GRUENENTHAL GMBH (DE) | 2010-02-03 | — | — | EP | claimed |
| US-20070015784-A1 | Subsitituted 1,4,8- triazaspiro [4,5]decan-2-one compounds | GRUENENTHAL GMBH (DE) | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015784-A1 | Subsitituted 1,4,8- triazaspiro [4,5]decan-2-one compounds | SI, SSTR4, SLC10A2 | GAA 143/4885HTT 914/4885SMN1; SMN2 2139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.